Nanomi is a health-focused startup that specializes in the development and production of long-acting release medicines. The company operates in the pharmaceutical industry, serving a broad range of clients including healthcare providers and patients. Nanomi's business model is centered around its proprietary Microsieve technology, which allows for the production of microspheres and nanoparticles used in their medicines. This technology ensures a highly controlled and reproducible production process, which is cost-effective and adheres to stringent quality standards.

Nanomi's products are designed to enhance patient compliance and convenience. Their medicines consist of biodegradable particles with active pharmaceutical compounds encapsulated within. The controlled and uniform particle size makes these medicines easier to inject, requiring smaller needles and causing less pain during injection. Furthermore, the release profile of the pharmaceutical compound can be accurately tailored and controlled over extended periods, reducing side effects caused by dose fluctuations. This results in optimal therapeutic benefits and improved therapy compliance.

The company is part of the Lupin group, a global pharmaceutical company known for developing and delivering a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Lupin operates in various medical fields, including cardiovascular, diabetes, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infective, and NSAID space.

In terms of revenue, Nanomi generates income through the sale of its innovative long-acting release medicines to healthcare providers and patients.

Keywords: Nanomi, Microsieve technology, long-acting release medicines, pharmaceutical industry, patient compliance, biodegradable particles, therapy compliance, Lupin group, pharmaceutical compounds, healthcare providers.